The use of phosphodiesterase type 5 inhibitors for erectile dysfunction.
Montorsi
Francesco
F
Department of Urology, Universitá Vita Salute San Raffaele, Via Olgettina 60, 20132 Milan, Italy. montorsi.francesco@hsr.it
Briganti
Alberto
A
Salonia
Andrea
A
Montorsi
Piero
P
Rigatti
Patrizio
P
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010727:Phosphoric Diester Hydrolases
D010726:Phosphodiesterase Inhibitors; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human